{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:12:07Z","timestamp":1792725127487,"version":"4.5.0"},"reference-count":184,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Botulinum neurotoxins (BoNTs) have been used for almost half a century in the treatment of excessive muscle contractility. BoNTs are routinely used to treat movement disorders such as cervical dystonia, spastic conditions, blepharospasm, and hyperhidrosis, as well as for cosmetic purposes. In addition to the conventional indications, the use of BoNTs to reduce pain has gained increased recognition, giving rise to an increasing number of indications in disorders associated with chronic pain. Furthermore, BoNT-derived formulations are benefiting a much wider range of patients suffering from overactive bladder, erectile dysfunction, arthropathy, neuropathic pain, and cancer. BoNTs are categorised into seven toxinotypes, two of which are in clinical use, and each toxinotype is divided into multiple subtypes. With the development of bioinformatic tools, new BoNT-like toxins have been identified in non-Clostridial organisms. In addition to the expanding indications of existing formulations, the rich variety of toxinotypes or subtypes in the wild-type BoNTs associated with new BoNT-like toxins expand the BoNT superfamily, forming the basis on which to develop new BoNT-based therapeutics as well as research tools. An overview of the diversity of the BoNT family along with their conventional therapeutic uses is presented in this review followed by the engineering and formulation opportunities opening avenues in therapy.<\/jats:p>","DOI":"10.3390\/toxins16060261","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T05:17:30Z","timestamp":1717478250000},"page":"261","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Embracing the Versatility of Botulinum Neurotoxins in Conventional and New Therapeutic Applications"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0661-695X","authenticated-orcid":false,"given":"Christine","family":"Rasetti-Escargueil","sequence":"first","affiliation":[{"name":"The Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Palea","sequence":"additional","affiliation":[{"name":"Humana Biosciences-Prologue Biotech, 516 Rue Pierre et Marie Curie, 31670 Lab\u00e8ge, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1212\/WNL.53.8.1850","article-title":"Historical aspects of botulinum toxin: Justinus Kerner (1786\u20131862) and the \u201csausage poison\u201d","volume":"53","author":"Erbguth","year":"1999","journal-title":"Neurology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/clinids\/1.4.701","article-title":"A New Anaerobic Bacillus and Its Relation to Botulism","volume":"1","year":"1979","journal-title":"Rev. Infect. Dis."},{"key":"ref_3","unstructured":"Nikolay, S. (2018). Botulinum Toxin, IntechOpen."},{"key":"ref_4","first-page":"174","article-title":"Botulinum treatment of strabismus in children","volume":"87","author":"Scott","year":"1989","journal-title":"Trans. Am. Ophthalmol. Soc."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Foster, K.A. (2014). Clinical Applications of Botulinum Neurotoxin, Springer.","DOI":"10.1007\/978-1-4939-0261-3"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1093\/gbe\/evw101","article-title":"Diversity of Group I and II Clostridium botulinum Strains from France Including Recently Identified Subtypes","volume":"8","author":"Mazuet","year":"2016","journal-title":"Genome Biol. Evol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/infdis\/154.2.207","article-title":"Two cases of type E infant botulism caused by neurotoxigenic Clostridium butyricum in Italy","volume":"154","author":"Aureli","year":"1986","journal-title":"J. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jama.285.8.1059","article-title":"Botulinum toxin as a biological weapon: Medical and public health management","volume":"285","author":"Arnon","year":"2001","journal-title":"JAMA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1128\/CMR.3.1.66","article-title":"Toxigenic clostridia","volume":"3","author":"Hatheway","year":"1990","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0041-0101(00)00163-X","article-title":"Tetanus and botulinum neurotoxins: Turning bad guys into good by research","volume":"39","author":"Rossetto","year":"2001","journal-title":"Toxicon"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1006\/bbrc.2001.5911","article-title":"Site-directed mutagenesis identifies active-site residues of the light chain of botulinum neurotoxin type A","volume":"288","author":"Rigoni","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1152\/physrev.2000.80.2.717","article-title":"Neurotoxins affecting neuroexocytosis","volume":"80","author":"Schiavo","year":"2000","journal-title":"Physiol. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Peck, M.W., Smith, T.J., Anniballi, F., Austin, J.W., Bano, L., Bradshaw, M., Cuervo, P., Cheng, L.W., Derman, Y., and Dorner, B. (2017). Historical Perspectives and Guidelines for Botulinum Neurotoxin Subtype Nomenclature. Toxins, 9.","DOI":"10.3390\/toxins9010038"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1017\/S0033583500003292","article-title":"Structure and function of tetanus and botulinum neurotoxins","volume":"28","author":"Montecucco","year":"1995","journal-title":"Q. Rev. Biophys."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev.biochem.051908.125345","article-title":"Botulinum neurotoxin: A marvel of protein design","volume":"79","author":"Montal","year":"2010","journal-title":"Annu. Rev. Biochem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.toxicon.2013.01.007","article-title":"Molecular dissection of botulinum neurotoxin reveals interdomain chaperone function","volume":"75","author":"Fischer","year":"2013","journal-title":"Toxicon"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbrc.2009.01.037","article-title":"The N-terminal half of the receptor domain of botulinum neurotoxin A binds to microdomains of the plasma membrane","volume":"380","author":"Muraro","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1078\/1438-4221-00152","article-title":"Lipid microdomains are involved in neurospecific binding and internalisation of clostridial neurotoxins","volume":"291","author":"Herreros","year":"2002","journal-title":"Int. J. Med. Microbiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1242\/jcs.112.16.2715","article-title":"Functional characterisation of tetanus and botulinum neurotoxins binding domains","volume":"112","author":"Lalli","year":"1999","journal-title":"J. Cell Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.1365-2672.1997.00313.x","article-title":"Phylogeny and taxonomy of the food-borne pathogen Clostridium botulinum and its neurotoxins","volume":"84","author":"Collins","year":"1998","journal-title":"J. Appl. Microbiol."},{"key":"ref_21","first-page":"21","article-title":"Assembly and function of the botulinum neurotoxin progenitor complex","volume":"364","author":"Gu","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1126\/science.1253823","article-title":"and R. Jin Molecular basis for disruption of E-cadherin adhesion by botulinum neurotoxin A complex","volume":"344","author":"Lee","year":"2014","journal-title":"Science"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.toxicon.2008.11.014","article-title":"A novel function of botulinum toxin-associated proteins: HA proteins disrupt intestinal epithelial barrier to increase toxin absorption","volume":"54","author":"Fujinaga","year":"2009","journal-title":"Toxicon"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/PL00007816","article-title":"Pharmacology and immunology of botulinum toxin serotypes","volume":"248","author":"Aoki","year":"2001","journal-title":"J. Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrmicro3295","article-title":"Botulinum neurotoxins: Genetic, structural and mechanistic insights","volume":"12","author":"Rossetto","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Gardner, A.P., and Barbieri, J.T. (2018). Light Chain Diversity among the Botulinum Neurotoxins. Toxins, 10.","DOI":"10.3390\/toxins10070268"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1615\/CritRevImmunol.v27.i4.20","article-title":"Botulinum neurotoxin vaccines: Past, present, and future","volume":"27","author":"Smith","year":"2007","journal-title":"Crit. Rev. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.fm.2010.03.005","article-title":"Clostridium botulinum in the post-genomic era","volume":"28","author":"Peck","year":"2011","journal-title":"Food Microbiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/infdis\/jit449","article-title":"A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins","volume":"209","author":"Barash","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/infdis\/jit450","article-title":"Molecular characterization of a novel botulinum neurotoxin type H gene","volume":"209","author":"Dover","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/infdis\/jiv327","article-title":"A Novel Botulinum Neurotoxin, Previously Reported as Serotype H, Has a Hybrid-Like Structure with Regions of Similarity to the Structures of Serotypes A and F and Is Neutralized with Serotype A Antitoxin","volume":"213","author":"Maslanka","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"14130","DOI":"10.1038\/ncomms14130","article-title":"and P. Stenmark. Identification and characterization of a novel botulinum neurotoxin","volume":"8","author":"Zhang","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.chom.2017.12.018","article-title":"Identification of a Botulinum Neurotoxin-like Toxin in a Commensal Strain of Enterococcus faecium","volume":"23","author":"Zhang","year":"2018","journal-title":"Cell Host Microbe"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1038\/s41467-019-10732-w","article-title":"A neurotoxin that specifically targets Anopheles mosquitoes","volume":"10","author":"Contreras","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Wei, X.W.T., Lobb, B., Mansfield, M., Zhen, W., Tan, H., Wu, Z., Pellett, S., Dong, M., and Doxey, A.C. (2022). Identification of divergent botulinum neurotoxin homologs in Paeniclostridium ghonii. bioRxiv.","DOI":"10.1101\/2022.08.17.504336"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.toxicon.2013.08.055","article-title":"Engineering Clostridia Neurotoxins with elevated catalytic activity","volume":"74","author":"Guo","year":"2013","journal-title":"Toxicon"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1038\/s41598-018-22842-4","article-title":"Structural characterisation of the catalytic domain of botulinum neurotoxin X-high activity and unique substrate specificity","volume":"8","author":"Masuyer","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Gregg, B.M., Matsumura, T., Wentz, T.G., Tepp, W.H., Bradshaw, M., Stenmark, P., Johnson, E.A., Fujinaga, Y., and Pellett, S. (2024). Botulinum neurotoxin X lacks potency in mice and in human neurons. mBio, 15.","DOI":"10.1128\/mbio.03106-23"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"30257","DOI":"10.1038\/srep30257","article-title":"The first non Clostridial botulinum-like toxin cleaves VAMP within the juxtamembrane domain","volume":"6","author":"Zornetta","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Smith, T.J., Schill, K.M., and Williamson, C.H.D. (2023). Navigating the Complexities Involving the Identification of Botulinum Neurotoxins (BoNTs) and the Taxonomy of BoNT-Producing Clostridia. Toxins, 15.","DOI":"10.3390\/toxins15090545"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1128\/mr.56.1.80-99.1992","article-title":"Properties and use of botulinum toxin and other microbial neurotoxins in medicine","volume":"56","author":"Schantz","year":"1992","journal-title":"Microbiol. Rev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e32371","DOI":"10.1097\/MD.0000000000032371","article-title":"Early development history of Botox (onabotulinumtoxinA)","volume":"102","author":"Scott","year":"2023","journal-title":"Medicine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"258","DOI":"10.7861\/clinmedicine.4-3-258","article-title":"The story of Clostridium botulinum: From food poisoning to Botox","volume":"4","author":"Ting","year":"2004","journal-title":"Clin. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00415-012-6615-2","article-title":"Botulinum toxin therapy: Its use for neurological disorders of the autonomic nervous system","volume":"260","author":"Dressler","year":"2013","journal-title":"J. Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00702-015-1478-1","article-title":"Botulinum toxin drugs: Brief history and outlook","volume":"123","author":"Dressler","year":"2016","journal-title":"J. Neural Transm."},{"key":"ref_46","first-page":"169","article-title":"Medical therapy and botulinum toxin in dystonia","volume":"78","author":"Jankovic","year":"1998","journal-title":"Adv. Neurol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJM199104253241707","article-title":"Therapeutic uses of botulinum toxin","volume":"324","author":"Jankovic","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Fonfria, E., Maignel, J., Lezmi, S., Martin, V., Splevins, A., SKalinichev, M., Foster, K., Picaut, P., and Krupp, J. (2018). The Expanding Therapeutic Utility of Botulinum Neurotoxins. Toxins, 10.","DOI":"10.3390\/toxins10050208"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.bjps.2008.03.023","article-title":"Botulinum toxin for treatment of glandular hypersecretory disorders","volume":"61","author":"Laing","year":"2008","journal-title":"J. Plast. Reconstr. Aesthet. Surg."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1055\/s-0035-1571215","article-title":"The Botulinum Toxin as a Therapeutic Agent: Molecular Structure and Mechanism of Action in Motor and Sensory Systems","volume":"36","author":"Kumar","year":"2016","journal-title":"Semin. Neurol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/j.1526-4610.2011.01990.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: Pooled analyses of the 56-week PREEMPT clinical program","volume":"51","author":"Aurora","year":"2011","journal-title":"Headache"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4196\/kjpp.2015.19.4.349","article-title":"Antinociceptive Effects of Transcytosed Botulinum Neurotoxin Type A on Trigeminal Nociception in Rats","volume":"19","author":"Kim","year":"2015","journal-title":"Korean J. Physiol. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1177\/0333102414527648","article-title":"Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains","volume":"34","author":"Burstein","year":"2014","journal-title":"Cephalalgia"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/bjd.16080","article-title":"The non-neuronal and nonmuscular effects of botulinum toxin: An opportunity for a deadly molecule to treat disease in the skin and beyond","volume":"178","author":"Grando","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1093\/asj\/sjx005","article-title":"New Uses of AbobotulinumtoxinA in Aesthetics","volume":"37","author":"Schlessinger","year":"2017","journal-title":"Aesthet. Surg. J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12640-021-00453-8","article-title":"The Effect of Botulinum Toxin on Hair Follicle Cell Regeneration Under Continuous Stress Conditions: A Pilot Animal Study","volume":"40","author":"Jung","year":"2022","journal-title":"Neurotox. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000317517","article-title":"The unusual history and the urological applications of botulinum neurotoxin","volume":"85","author":"Hanchanale","year":"2010","journal-title":"Urol. Int."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Anandan, C., and Jankovic, J. (2021). Botulinum Toxin in Movement Disorders: An Update. Toxins, 13.","DOI":"10.3390\/toxins13010042"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Scaglione, F. (2016). Conversion Ratio between Botox\u00ae, Dysport\u00ae, and Xeomin\u00ae in Clinical Practice. Toxins, 8.","DOI":"10.3390\/toxins8030065"},{"key":"ref_60","unstructured":"(2024, April 09). DAXXIFY\u00ae Becomes First Facial Injectable to be Named to TIME\u2019s Best Inventions. Available online: https:\/\/www.businesswire.com\/news\/home\/20231026772907\/en\/DAXXIFY%C2%AE-Becomes-First-Facial-Injectable-to-be-Named-to-TIME%E2%80%99s-Best-Inventions."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1007\/s40265-021-01631-w","article-title":"Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A","volume":"81","author":"Solish","year":"2021","journal-title":"Drugs"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.toxicon.2019.12.005","article-title":"Therapeutically relevant features of botulinum toxin drugs","volume":"175","author":"Dressler","year":"2020","journal-title":"Toxicon"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/asj\/sjw284","article-title":"Monheit, Andy Pickett AbobotulinumtoxinA: A 25-Year History","volume":"37","author":"Gary","year":"2017","journal-title":"Aesthet. Surg. J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e49516","DOI":"10.1371\/journal.pone.0049516","article-title":"Botulinum neurotoxin serotype A specific cell-based potency assay to replace the mouse bioassay","volume":"7","author":"Wang","year":"2012","journal-title":"PLoS ONE"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Rasetti-Escargueil, C., Lemichez, E., and Popoff, M.R. (2018). Variability of Botulinum Toxins: Challenges and Opportunities for the Future. Toxins, 10.","DOI":"10.3390\/toxins10090374"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00702-022-02494-5","article-title":"Botulinum toxin therapy: Past, present and future developments","volume":"129","author":"Dressler","year":"2022","journal-title":"J. Neural Transm."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Choudhury, S., Baker, M.R., Chatterjee, S., and Kumar, H. (2021). Botulinum Toxin: An Update on Pharmacology and Newer Products in Development. Toxins, 13.","DOI":"10.3390\/toxins13010058"},{"key":"ref_68","first-page":"143","article-title":"Role of proteolytic enzyme in toxin production by clostridium botulinum type A","volume":"11","author":"Inukai","year":"1963","journal-title":"Jpn. J. Vet. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jpba.2010.08.013","article-title":"Release of proteolytic activity following reduction in therapeutic human serum albumin containing products: Detection with a new neoepitope endopeptidase immunoassay","volume":"54","author":"Jones","year":"2011","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_70","first-page":"227","article-title":"Botulinum toxin type A products are not interchangeable: A review of the evidence","volume":"8","author":"Brin","year":"2014","journal-title":"Biologics"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e00446","DOI":"10.1002\/prp2.446","article-title":"A comparison of biological activity of commercially available purified native botulinum neurotoxin serotypes A1 to F1 in vitro, ex vivo, and in vivo","volume":"6","author":"Donald","year":"2018","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"413e","DOI":"10.1097\/PRS.0b013e318170813c","article-title":"Comparisons among botulinum toxins: An evidence-based review","volume":"121","author":"Klein","year":"2008","journal-title":"Plast. Reconstr. Surg."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Takeuchi, T., Okuno, T., Miyashiro, A., Kohda, T., Miyamoto, R., Izumi, Y., Kozaki, S., and Kaji, R. (2021). Clinical Safety and Tolerability of A2NTX, a Novel Low-Molecular-Weight Neurotoxin Derived from Botulinum Neurotoxin Subtype A2, in Comparison with Subtype A1 Toxins. Toxins, 13.","DOI":"10.20944\/preprints202110.0121.v1"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Spiegel, L.L., Ostrem, J.L., and Bledsoe, I.O. (2020). FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia. Toxins, 12.","DOI":"10.3390\/toxins12050332"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1007\/s00415-015-7703-x","article-title":"Practical guidance for CD management involving treatment of botulinum toxin: A consensus statement","volume":"262","author":"Albanese","year":"2015","journal-title":"J. Neurol."},{"key":"ref_76","unstructured":"FDA (2024, April 08). BOTOX (onabotulinumtoxinA) Label. Allergan, Inc. U.S. U.S. Food and Drug Administration Website, Available online: https:\/\/www.accessdata.fda.gov\/Drugsatfda_docs\/Label\/2011\/103000s5236lbl.Pdf."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/SPV.0000000000000316","article-title":"Characterizing the Bladder\u2019s Response to Onabotulinum Toxin Type A Using a Rat Model","volume":"22","author":"Dieter","year":"2016","journal-title":"Female Pelvic. Med. Reconstr. Surg."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.purol.2022.12.010","article-title":"Intradetrusor botulinum toxin as the first-line treatment for neurogenic detrusor overactivity: Pro","volume":"33","author":"Denys","year":"2023","journal-title":"Prog. Urol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"625","DOI":"10.23736\/S2724-6051.21.04227-2","article-title":"IncobotulinumtoxinA versus onabotulinumtoxinA intradetrusor injections in patients with neurogenic detrusor overactivity incontinence: A double-blind, randomized, non-inferiority trial","volume":"74","author":"Giannantoni","year":"2022","journal-title":"Minerva Urol. Nephrol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Maignel, J., Martin, V., Assaly, R., Vogt, M.L., Retailleau, K., Hornby, F., Laugerotte, A., Lezmi, S., Denys, P., and Krupp, J. (2022). BoNT\/A1 Secondary Failure for the Treatment of Neurogenic Detrusor Overactivity: An Ex Vivo Functional Study. Toxins, 14.","DOI":"10.3390\/toxins14020077"},{"key":"ref_81","first-page":"507","article-title":"Poster 670, 43rd Annual Meeting of the International Continence Society","volume":"32","author":"Andretta","year":"2013","journal-title":"Neurourol. Urodyn."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11599840-000000000-00000","article-title":"Clinical relevance of botulinum toxin immunogenicity","volume":"26","author":"Benecke","year":"2012","journal-title":"BioDrugs"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1016\/j.juro.2016.10.109","article-title":"OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial","volume":"197","author":"Nitti","year":"2017","journal-title":"J. Urol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/iju.14176","article-title":"OnabotulinumtoxinA (botulinum toxin type A) for the treatment of Japanese patients with overactive bladder and urinary incontinence: Results of single-dose treatment from a phase III, randomized, double-blind, placebo-controlled trial (interim analysis)","volume":"27","author":"Yokoyama","year":"2020","journal-title":"Int. J. Urol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/01.ju.0000165452.39125.98","article-title":"Finnish Interstitial Cystitis-Pelvic Pain Syndrome Study Group Prevalence of clinically confirmed interstitial cystitis in women: A population based study in Finland","volume":"174","author":"Leppilahti","year":"2005","journal-title":"J. Urol."},{"key":"ref_86","first-page":"109","article-title":"Intravesical botulinum toxin a injections do not benefit patients with ulcer type interstitial cystitis","volume":"16","author":"Lee","year":"2013","journal-title":"Pain Physician"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.juro.2017.10.018","article-title":"Intratrigonal OnabotulinumtoxinA Improves Bladder Symptoms and Quality of Life in Patients with Bladder Pain Syndrome\/Interstitial Cystitis: A Pilot, Single Center, Randomized, Double-Blind, Placebo Controlled Trial","volume":"199","author":"Pinto","year":"2018","journal-title":"J. Urol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.juro.2017.02.021","article-title":"A Prospective, Multicenter, Double-Blind, Randomized Trial of Bladder Instillation of Liposome Formulation OnabotulinumtoxinA for Interstitial Cystitis\/Bladder Pain Syndrome","volume":"198","author":"Chuang","year":"2017","journal-title":"J. Urol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.sxmr.2020.01.003","article-title":"Application of Botulinum Neurotoxin in Female Sexual and Genitourinary Dysfunction: A Review of Current Practices","volume":"9","author":"Dick","year":"2021","journal-title":"Sex. Med. Rev."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.sxmr.2020.05.004","article-title":"Application of Botulinum Neurotoxin in Male Sexual Dysfunction: Where Are We Now?","volume":"9","author":"Reddy","year":"2021","journal-title":"Sex. Med. Rev."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.sxmr.2017.07.008","article-title":"Botulinum Neurotoxin and Its Potential Role in the Treatment of Erectile Dysfunction","volume":"6","author":"Ghanem","year":"2018","journal-title":"Sex. Med. Rev."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jsxm.2017.04.662","article-title":"Re: Botox for Erectile Dysfunction","volume":"14","author":"Ghanem","year":"2017","journal-title":"J. Sex. Med."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Giuliano, F., Denys, P., and Joussain, C. (2023). Safety and Effectiveness of Repeated Botulinum Toxin A Intracavernosal Injections in Men with Erectile Dysfunction Unresponsive to Approved Pharmacological Treatments: Real-World Observational Data. Toxins, 15.","DOI":"10.3390\/toxins15060382"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Giuliano, F., Denys, P., and Joussain, C. (2022). Effectiveness and Safety of Intracavernosal IncobotulinumtoxinA (Xeomin\u00ae) 100 U as an Add-on Therapy to Standard Pharmacological Treatment for Difficult-to-Treat Erectile Dysfunction: A Case Series. Toxins, 14.","DOI":"10.3390\/toxins14040286"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jsxm.2021.10.011","article-title":"Long Term Effectiveness and Safety of Intracavernosal Botulinum Toxin A as an Add-on Therapy to Phosphosdiesterase Type 5 Inhibitors or Prostaglandin E1 Injections for Erectile Dysfunction","volume":"19","author":"Giuliano","year":"2022","journal-title":"J. Sex. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jsxm.2022.03.213","article-title":"Intracavernosal OnabotulinumtoxinA Exerts a Synergistic Pro-Erectile Effect When Combined With Sildenafil in Spontaneously Hypertensive Rats","volume":"19","author":"Giuliano","year":"2022","journal-title":"J. Sex. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/epirev\/mxt009","article-title":"The prevalence and risk factors of dysmenorrhea","volume":"36","author":"Ju","year":"2014","journal-title":"Epidemiol. Rev."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1148\/radiol.2351031283","article-title":"Dysmenorrhea: Evaluation with cine-mode-display MR imaging--initial experience","volume":"235","author":"Kataoka","year":"2005","journal-title":"Radiology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"101972","DOI":"10.1016\/j.jogoh.2020.101972","article-title":"Treatment of acute dysmenorrhoea and pelvic pain syndrome of uterine origin with myometrial botulinum toxin injections under hysteroscopy: A pilot study","volume":"50","author":"Bautrant","year":"2021","journal-title":"J. Gynecol. Obstet. Hum. Reprod."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"101354","DOI":"10.1016\/j.rehab.2019.12.009","article-title":"Botulinum toxin infiltrations versus local anaesthetic infiltrations in pelvic floor myofascial pain: Multicentre, randomized, double-blind study","volume":"64","author":"Levesque","year":"2021","journal-title":"Ann. Phys. Rehabil. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejogrb.2023.04.019","article-title":"Uterine botulinum toxin injections in severe dysmenorrhea, dyspareunia and chronic pelvic pain: Results on quality of life, pain level and medical consumption","volume":"285","author":"Leveque","year":"2023","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0300-9084(00)00216-9","article-title":"How botulinum and tetanus neurotoxins block neurotransmitter release","volume":"82","author":"Humeau","year":"2000","journal-title":"Biochimie"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ana.21427","article-title":"Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain","volume":"64","author":"Ranoux","year":"2008","journal-title":"Ann. Neurol."},{"key":"ref_104","first-page":"133","article-title":"Botulinum Toxin Can Abolish and\/or Quiet Tinnitus Associated with Chronic Migraine: Serendipidous Observations","volume":"25","author":"Ranoux","year":"2022","journal-title":"Int. Tinnitus J."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1129-2377-15-65","article-title":"Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: Observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial","volume":"15","author":"Zhang","year":"2014","journal-title":"J. Headache Pain"},{"key":"ref_106","first-page":"e2","article-title":"The Use of Botulinum Toxin A in the Management of Trigeminal Neuralgia: A Systematic Literature Review","volume":"11","author":"Rubis","year":"2020","journal-title":"J. Oral Maxillofac. Res."},{"key":"ref_107","first-page":"e26856","article-title":"Therapeutic Efficacy of Botulinum Toxin in Trigeminal Neuralgia","volume":"14","author":"Kayani","year":"2022","journal-title":"Cureus"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.parkreldis.2015.03.027","article-title":"Botulinum Toxin-A for treatment of Pisa syndrome: A new target muscle","volume":"21","author":"Dupeyron","year":"2015","journal-title":"Park. Relat. Disord."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Munoz-Lora, V.R.M., Dugonjic Okrosa, A., Matak, I., Del Bel Cury, A.A., Kalinichev, M., and Lackovic, Z. (2022). Antinociceptive Actions of Botulinum Toxin A1 on Immunogenic Hypersensitivity in Temporomandibular Joint of Rats. Toxins, 14.","DOI":"10.3390\/toxins14030161"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Luvisetto, S. (2022). Botulinum Neurotoxins beyond Neurons: Interplay with Glial Cells. Toxins, 14.","DOI":"10.3390\/toxins14100704"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Luvisetto, S. (2021). Botulinum Neurotoxins in Central Nervous System: An Overview from Animal Models to Human Therapy. Toxins, 13.","DOI":"10.3390\/toxins13110751"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/JPR.S12520","article-title":"Analgesic effects of intra-articular botulinum toxin Type B in a murine model of chronic degenerative knee arthritis pain","volume":"3","author":"Anderson","year":"2010","journal-title":"J. Pain Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1080\/14740338.2017.1344211","article-title":"The safety of intra-articular injections for the treatment of knee osteoarthritis: A critical narrative review","volume":"16","author":"Nguyen","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e022337","DOI":"10.1136\/bmjopen-2018-022337","article-title":"Intra-articular botulinum toxin A for base-of-thumb osteoarthritis: Protocol for a randomised trial (RHIBOT)","volume":"8","author":"Gil","year":"2018","journal-title":"BMJ Open"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1001\/archotol.128.8.956","article-title":"Head and neck muscle spasm after radiotherapy: Management with botulinum toxin A injection","volume":"128","author":"Finnegan","year":"2002","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.canrad.2019.02.001","article-title":"Radiation-induced head and neck pain: Management with botulinum toxin a injections","volume":"23","author":"Mailly","year":"2019","journal-title":"Cancer Radiother."},{"key":"ref_117","first-page":"40","article-title":"Botulinum Toxin for Side-Effect Management and Prevention of Surgical Complications in Patients Treated for Head and Neck Cancers and Esophageal Cancer","volume":"10","author":"Shaw","year":"2019","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"168","DOI":"10.14639\/0392-100X-1608","article-title":"Botulinum toxin therapy: Functional silencing of salivary disorders","volume":"37","author":"Lovato","year":"2017","journal-title":"Acta Otorhinolaryngol. Ital."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"209e","DOI":"10.1097\/PRS.0000000000000371","article-title":"Classification of masseter hypertrophy for tailored botulinum toxin type A treatment","volume":"134","author":"Xie","year":"2014","journal-title":"Plast. Reconstr. Surg."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.joms.2016.01.038","article-title":"Use of Botox (OnabotulinumtoxinA) for the Treatment of Parotid Sialocele and Fistula After Extirpation of Buccal Squamous Cell Carcinoma With Immediate Reconstruction Using Microvascular Free Flap: A Report of 3 Cases","volume":"74","author":"Melville","year":"2016","journal-title":"J. Oral. Maxillofac. Surg."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/SAP.0000000000001622","article-title":"Botulinum Toxin Injection for Lower Face and Oral Cavity Raynaud Phenomenon After Mandibulectomy, Free Fibula Reconstruction, and Radiation Therapy","volume":"82","author":"Boukovalas","year":"2019","journal-title":"Ann. Plast. Surg."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Ulloa, F., Gonzalez-Junca, A., Meffre, D., Barrecheguren, P.J., Martinez-Marmol, R., Pazos, I., Oliv\u00e9, N., Cotrufo, T., Seoane, J., and Soriano, E. (2015). Blockade of the SNARE protein syntaxin 1 inhibits glioblastoma tumor growth. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0119707"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.humpath.2016.02.001","article-title":"Biologic effect of neurogenesis in pancreatic cancer","volume":"52","author":"He","year":"2016","journal-title":"Hum. Pathol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.tox.2015.07.003","article-title":"Botulinum neurotoxin type A: Actions beyond SNAP-25?","volume":"335","author":"Matak","year":"2015","journal-title":"Toxicology"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"891","DOI":"10.7314\/APJCP.2013.14.2.891","article-title":"Effect of botulinum toxin A on proliferation and apoptosis in the T47D breast cancer cell line","volume":"14","author":"Bandala","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"101152","DOI":"10.1016\/j.nmni.2023.101152","article-title":"Outbreaks of iatrogenic botulism in Europe: Combating off-label medical use of Botulinum Neurotoxin (BoNT) in bariatric procedures","volume":"53","author":"Jain","year":"2023","journal-title":"New Microbes New Infect."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/2338","article-title":"Crystal structure of botulinum neurotoxin type A and implications for toxicity","volume":"5","author":"Lacy","year":"1998","journal-title":"Nat. Struct. Biol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jmb.2008.12.027","article-title":"Domain organization in Clostridium botulinum neurotoxin type E is unique: Its implication in faster translocation","volume":"386","author":"Kumaran","year":"2009","journal-title":"J. Mol. Biol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s00018-005-5505-5","article-title":"Clostridial neurotoxins: Structure-function led design of new therapeutics","volume":"63","author":"Chaddock","year":"2006","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Fonfria, E., Elliott, M., Beard, M., Chaddock, J.A., and Krupp, J. (2018). Engineering Botulinum Toxins to Improve and Expand Targeting and SNARE Cleavage Activity. Toxins, 10.","DOI":"10.3390\/toxins10070278"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1124\/pr.116.012658","article-title":"Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology","volume":"69","author":"Pirazzini","year":"2017","journal-title":"Pharmacol. Rev."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"eaau7196","DOI":"10.1126\/sciadv.aau7196","article-title":"Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models","volume":"5","author":"Elliott","year":"2019","journal-title":"Sci. Adv."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1074\/jbc.M209821200","article-title":"Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons","volume":"278","author":"Foran","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"E5158","DOI":"10.1073\/pnas.1621076114","article-title":"Deubiquitinating enzyme VCIP135 dictates the duration of botulinum neurotoxin type A intoxication","volume":"114","author":"Tsai","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Kohda, T., Nakamura, K., Hosomi, K., Torii, Y., Kozaki, S., and Mukamoto, M. (2017). Response to \u201cStandardized methods must be used to compare the properties of botulinum toxin serotypes\u201d. Microbiol. Immunol., 61.","DOI":"10.1111\/1348-0421.12552"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.toxicon.2020.02.020","article-title":"Clinical duration of action of different botulinum toxin types in humans","volume":"179","author":"Eleopra","year":"2020","journal-title":"Toxicon"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuro.2016.12.008","article-title":"BoNT\/AB hybrid maintains similar duration of paresis as BoNT\/A wild-type in murine running wheel assay","volume":"59","author":"Kutschenko","year":"2017","journal-title":"Neurotoxicology"},{"key":"ref_138","first-page":"107444","article-title":"Sondergaard editor Botulinum Neurotoxin Type DC (BoNT\/DC) Blocks Melanocyte Melanogenesis","volume":"237","author":"Malik","year":"2024","journal-title":"Toxins"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Whitemarsh, R.C., Tepp, W.H., Johnson, E.A., and Pellett, S. (2014). Persistence of botulinum neurotoxin a subtypes 1\u20135 in primary rat spinal cord cells. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090252"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.toxicon.2019.06.004","article-title":"Comparative functional analysis of mice after local injection with botulinum neurotoxin A1, A2, A6, and B1 by catwalk analysis","volume":"167","author":"Moritz","year":"2019","journal-title":"Toxicon"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.febslet.2010.11.045","article-title":"Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1","volume":"585","author":"Pier","year":"2011","journal-title":"FEBS Lett."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1080\/19420862.2015.1082016","article-title":"Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B","volume":"7","author":"Avril","year":"2015","journal-title":"MAbs"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1128\/AEM.07967-11","article-title":"Purification and characterization of a novel subtype a3 botulinum neurotoxin","volume":"78","author":"Tepp","year":"2012","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jsb.2017.12.010","article-title":"High resolution crystal structures of Clostridium botulinum neurotoxin A3 and A4 binding domains","volume":"202","author":"Davies","year":"2018","journal-title":"J. Struct. Biol."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Tian, R., Widel, M., and Imanian, B. (2022). The Light Chain Domain and Especially the C-Terminus of Receptor-Binding Domain of the Botulinum Neurotoxin (BoNT) Are the Hotspots for Amino Acid Variability and Toxin Type Diversity. Genes, 13.","DOI":"10.3390\/genes13101915"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1021\/bi801686b","article-title":"Catalytic properties of botulinum neurotoxin subtypes A3 and A4","volume":"48","author":"Henkel","year":"2009","journal-title":"Biochemistry"},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Tepp, W.H., Bradshaw, M., Gardner, A.P., Kaufman, R.L., Barbieri, J.T., and Pellett, S. (2023). Botulinum Neurotoxin A4 Has a 1000-Fold Reduced Potency Due to Three Single Amino Acid Alterations in the Protein Receptor Binding Domain. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065690"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Yin, L., Masuyer, G., Zhang, S., Zhang, J., Miyashita, S.I., Burgin, D., Lovelock, L., Coker, S.F., Fu, T.M., and Stenmark, P. (2020). Characterization of a membrane binding loop leads to engineering botulinum neurotoxin B with improved therapeutic efficacy. PLoS Biol., 18.","DOI":"10.1371\/journal.pbio.3000618"},{"key":"ref_149","unstructured":"Steward, L., Brin, M.F., and Brideau-Andersen, A. (2020). Handbook of Experimental Pharmacology, Springer."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1111\/j.1742-4658.2011.08205.x","article-title":"Novel therapeutics based on recombinant botulinum neurotoxins to normalize the release of transmitters and pain mediators","volume":"278","author":"Dolly","year":"2011","journal-title":"FEBS J."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"16993","DOI":"10.1074\/jbc.M710442200","article-title":"Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics","volume":"283","author":"Wang","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.coph.2011.11.001","article-title":"Neurotherapeutics to inhibit exocytosis from sensory neurons for the control of chronic pain","volume":"12","author":"Dolly","year":"2012","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.neuropharm.2017.03.026","article-title":"A novel therapeutic with two SNAP-25 inactivating proteases shows long-lasting anti-hyperalgesic activity in a rat model of neuropathic pain","volume":"118","author":"Wang","year":"2017","journal-title":"Neuropharmacology"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Elliott, M., Maignel, J., Liu, S.M., Favre-Guilmard, C., Mir, I., Farrow, P., Hornby, F., Marlin, S., Palan, S., and Beard, M. (2017). Augmentation of VAMP-catalytic activity of botulinum neurotoxin serotype B does not result in increased potency in physiological systems. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0185628"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1021\/bi200290p","article-title":"Syntaxin requirement for Ca2+-triggered exocytosis in neurons and endocrine cells demonstrated with an engineered neurotoxin","volume":"50","author":"Wang","year":"2011","journal-title":"Biochemistry"},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Zanetti, G., Sikorra, S., Rummel, A., Krez, N., Duregotti, E., Negro, S., Henke, T., Rossetto, O., Binz, T., and Pirazzini, M. (2017). Botulinum neurotoxin C mutants reveal different effects of syntaxin or SNAP-25 proteolysis on neuromuscular transmission. PLoS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006567"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.bbrc.2012.11.048","article-title":"Time course and temperature dependence of the membrane translocation of tetanus and botulinum neurotoxins C and D in neurons","volume":"430","author":"Pirazzini","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1432-1033.1987.tb13320.x","article-title":"A 50-kDa fragment from the NH2-terminus of the heavy subunit of Clostridium botulinum type A neurotoxin forms channels in lipid vesicles","volume":"167","author":"Shone","year":"1987","journal-title":"Eur. J. Biochem."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1432-1033.1985.tb09070.x","article-title":"Inactivation of Clostridium botulinum type A neurotoxin by trypsin and purification of two tryptic fragments. Proteolytic action near the COOH-terminus of the heavy subunit destroys toxin-binding activity","volume":"151","author":"Shone","year":"1985","journal-title":"Eur. J. Biochem."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1128\/IAI.68.5.2587-2593.2000","article-title":"Inhibition of vesicular secretion in both neuronal and nonneuronal cells by a retargeted endopeptidase derivative of Clostridium botulinum neurotoxin type A","volume":"68","author":"Chaddock","year":"2000","journal-title":"Infect. Immun."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1046-5928(02)00002-5","article-title":"Expression and purification of catalytically active, non-toxic endopeptidase derivatives of Clostridium botulinum toxin type A","volume":"25","author":"Chaddock","year":"2002","journal-title":"Protein Expr. Purif."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF03354881","article-title":"Re-engineering the target specificity of Clostridial neurotoxins\u2014A route to novel therapeutics","volume":"9","author":"Foster","year":"2006","journal-title":"Neurotox. Res."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"18197","DOI":"10.1073\/pnas.1007125107","article-title":"SNARE tagging allows stepwise assembly of a multimodular medicinal toxin","volume":"107","author":"Darios","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3390\/toxins3040345","article-title":"Re-assembled botulinum neurotoxin inhibits CNS functions without systemic toxicity","volume":"3","author":"Ferrari","year":"2011","journal-title":"Toxins"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuropharm.2018.06.016","article-title":"A SNAP-25 cleaving chimera of botulinum neurotoxin\/A and \/E prevents TNFalpha-induced elevation of the activities of native TRP channels on early postnatal rat dorsal root ganglion neurons","volume":"138","author":"Nugent","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"9180","DOI":"10.1073\/pnas.0903111106","article-title":"Engineering botulinum neurotoxin to extend therapeutic intervention","volume":"106","author":"Chen","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"23707","DOI":"10.1038\/srep23707","article-title":"Retargeting the Clostridium botulinum C2 toxin to the neuronal cytosol","volume":"6","author":"Pavlik","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"42923","DOI":"10.1038\/srep42923","article-title":"Engineering Botulinum Neurotoxin C1 as a Molecular Vehicle for Intra-Neuronal Drug Delivery","volume":"7","author":"Beske","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Tang, M., Meng, J., and Wang, J. (2019). New Engineered-Botulinum Toxins Inhibit the Release of Pain-Related Mediators. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21010262"},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Miyashita, S.I., Karatsu, S., Fujiishi, M., Huang, I.H., Nagashima, Y., Morobishi, T., Hosoya, K., Hata, T., Dong, M., and Sagane, Y. (2023). Characterization of Serotype CD Mosaic Botulinum Neurotoxin in Comparison with Serotype C and A. Toxins, 15.","DOI":"10.3390\/toxins15020123"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"100019","DOI":"10.1016\/j.toxcx.2019.100019","article-title":"Duplication of clostridial binding domains for enhanced macromolecular delivery into neurons","volume":"5","author":"Leese","year":"2020","journal-title":"Toxicon X"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"e202201631","DOI":"10.26508\/lsa.202201631","article-title":"New botulinum neurotoxin constructs for treatment of chronic pain","volume":"6","author":"Leese","year":"2023","journal-title":"Life Sci. Alliance"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1038\/s41467-023-37860-8","article-title":"Structural basis for botulinum neurotoxin E recognition of synaptic vesicle protein 2","volume":"14","author":"Liu","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"116516","DOI":"10.1016\/j.jns.2019.116516","article-title":"Safety and pharmacodynamics of a novel recombinant botulinum toxin E (rBoNT-E): Results of a phase 1 study in healthy male subjects compared with abobotulinumtoxinA (Dysport\u00ae)","volume":"407","author":"Pons","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"107377","DOI":"10.1016\/j.toxicon.2024.107377","article-title":"Evaluation of Botulinum Neurotoxin type E preparation (TrenibotulinumtoxinE) in the mouse digit abduction score (DAS) assay","volume":"237","author":"Canty","year":"2024","journal-title":"Toxicon"},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Machicoane, M., Tonellato, M., Zainotto, M., Onillon, P., Stazi, M., Dal Corso, M., Megighian, A., Rossetto, O., Le Doussal, J.M., and Pirazzini, M. (2024). Excitation-Contraction Coupling Inhibitors Potentiate the Activity of Botulinum Neurotoxin Type A at the Neuromuscular Junction. Toxicon, 237.","DOI":"10.1016\/j.toxicon.2024.107441"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"107452","DOI":"10.1016\/j.toxicon.2024.107452","article-title":"Structure-Based Design of a Botulinum Neurotoxin With Triple Receptor Recognition","volume":"237","author":"Masuyer","year":"2024","journal-title":"Toxicon"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3109\/21681805.2015.1121406","article-title":"Intravesical instillation of onabotulinum toxin A embedded in inert hydrogel in the treatment of idiopathic overactive bladder: A double-blind randomized pilot study","volume":"50","author":"Krhut","year":"2016","journal-title":"Scand. J. Urol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"7784","DOI":"10.1039\/D3BM01301D","article-title":"Botulinum toxin A dissolving microneedles for hyperhidrosis treatment: Design, formulation and in vivo evaluation","volume":"11","author":"Shafiei","year":"2023","journal-title":"Biomater. Sci."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"107264","DOI":"10.1016\/j.toxicon.2023.107264","article-title":"A look at the future-new BoNTs and delivery systems in development: What it could mean in the clinic","volume":"234","author":"Kaji","year":"2023","journal-title":"Toxicon"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"11778","DOI":"10.1038\/s41598-023-38618-4","article-title":"Preclinical characterization of the efficacy and safety of biologic N-001 as a novel pain analgesic for post-operative acute pain treatment","volume":"13","author":"Allen","year":"2023","journal-title":"Sci Rep."},{"key":"ref_182","first-page":"321","article-title":"Optogenetics: Therapeutic spark in neuropathic pain","volume":"19","author":"Liu","year":"2019","journal-title":"Bosn. J. Basic Med. Sci."},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Joussain, C., Le Coz, O., Pichugin, A., Marconi, P., Lim, F., Sicurella, M., Salonia, A., Montorsi, F., Wandosell, F., and Foster, K. (2019). Botulinum Neurotoxin Light Chains Expressed by Defective Herpes Simplex Virus Type-1 Vectors Cleave SNARE Proteins and Inhibit CGRP Release in Rat Sensory Neurons. Toxins, 11.","DOI":"10.3390\/toxins11020123"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"S232","DOI":"10.1016\/S0378-4274(23)00798-1","article-title":"P20-01: First certified reference materials (CRMs) to improve the reliability of biological toxins detection, identification and quantification","volume":"384","author":"Zeleny","year":"2023","journal-title":"Toxicol. Lett."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/16\/6\/261\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:53:26Z","timestamp":1760108006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/16\/6\/261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":184,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["toxins16060261"],"URL":"https:\/\/doi.org\/10.3390\/toxins16060261","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,4]]}}}